
dBET1
CAS No. 1799711-21-9
dBET1 ( dBET 1 )
产品货号. M12725 CAS No. 1799711-21-9
dBET1 是一种蛋白水解靶向嵌合体 (PROTAC) 分子,它将 BET 溴结构域 (JQ1) 的竞争性拮抗剂附加到邻苯二甲酰亚胺部分以劫持 cereblon E3 泛素连接酶复合物。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥543 | 有现货 |
![]() ![]() |
5MG | ¥786 | 有现货 |
![]() ![]() |
10MG | ¥1442 | 有现货 |
![]() ![]() |
25MG | ¥3013 | 有现货 |
![]() ![]() |
50MG | ¥4504 | 有现货 |
![]() ![]() |
100MG | ¥6342 | 有现货 |
![]() ![]() |
500MG | ¥13365 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称dBET1
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述dBET1 是一种蛋白水解靶向嵌合体 (PROTAC) 分子,它将 BET 溴结构域 (JQ1) 的竞争性拮抗剂附加到邻苯二甲酰亚胺部分以劫持 cereblon E3 泛素连接酶复合物。
-
产品描述dBET1 is a proteolysis-targeting chimera (PROTAC) molecule that appendes a competitive antagonist of BET bromodomain (JQ1) to a phthalimide moiety to hijack the cereblon E3 ubiquitin ligase complex; induces highly selective cereblon-dependent BET protein degradation in vitro (EC50=430 nM) and in vivo and delayed leukemia progression in mice.
-
体外实验Treatment with dBET1 down regulates MYC and PIM1 transcription. Degradation of BRD4 by dBET1 is associated with a more potent apoptotic consequence in MV4;11 cell line. Significantly increased apoptosis after only 4 h of dBET1 treatment is enhanced at 8 h. dBET1 also induces a potent and superior inhibitory effect on MV4;11 cell proliferation at 24 hours (measured by ATP content, IC50= 0.14 μM, compare to IC50= 1.1 μM with JQ1).
-
体内实验Administration of dBET1 attenuates tumor progression as determined by serial volumetric measurement, and decreases tumor weight assessed post-mortem. Acute pharmacodynamic degradation of BRD4 is observed four hours after a first or second daily treatment with dBET1 (50 mg/kg IP). A statistically significant destabilization of BRD4, down regulation of MYC and inhibition of proliferation is observed with dBET1 compare to vehicle control in excised tumors. Two weeks of dBET1 is well tolerated by mice without a meaningful effect on weight, white blood count, hematocrit or platelet count.
-
同义词dBET 1
-
通路PROTACs
-
靶点PROTAC
-
受体BET
-
研究领域——
-
适应症——
化学信息
-
CAS Number1799711-21-9
-
分子量785.273
-
分子式C38H37ClN8O7S
-
纯度>98% (HPLC)
-
溶解度DMSO: 50 mg/mL; Water: Insoluble; Ethanol: 5 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESCC(N(C1C2=NN=C(C)N2C3=C(C(C)=C(C)S3)C(C4=CC=C(Cl)C=C4)=N1)CCCCNC(COC5=CC=CC(C(N6C(CC7)C(NC7=O)=O)=O)=C5C6=O)=O)=O
-
化学全称(6S)-4-(4-chlorophenyl)-N-[4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]butyl]-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Winter GE, et al. Science. 2015 Jun 19;348(6241):1376-81.
产品手册




关联产品
-
DADPS Biotin Azide
Biotin-PEG4-amino-t-Bu-DADPS-C6-azide 是一种 PROTAC linker,属于 PEG 类。可用于合成 PROTAC 分子。Biotin-PEG4-amino-t-Bu-DADPS-C6-azide 是一种点击化学试剂。它含有 Azide 基团,可以和含有 Alkyne 基团的分子发生铜催化的叠氮-炔环加成反应(CuAAc)。还可以和含有 DBCO 或 BCN 基团的分子发生菌株促进的炔-叠氮环加成反应 (SPAAC)。
-
Hydroxy-PEG6-Boc
Hydroxy-PEG7-Boc 是一种基于 PEG 的 PROTAC 连接体,可用于 PROTAC 的合成。
-
JH-XI-10-02
JH-XI-10-02 是一种基于 CDK8 抑制剂 JH-VIII-49 的 CDK8 PROTAC,可诱导 Jurkat 细胞中 CDK8 部分降解,IC50 为 159 nM。